No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
XORTX Therapeutics Announces Type B Meeting With FDA
XORTX Therapeutics Inc (XRTX) Gets a Buy From Alliance Global Partners
XORTX Therapeutics up 8.3% as It Launches a New Program to Treat Gout
XORTX Therapeutics Names Michael Bumby as CFO; U.S.-listed Shares Down 4%
XORTX Therapeutics Inc. Faces Financial Challenges
XORTX Initiates Precision Medicine Program